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This review paper is dedicated to ways of production and medical ap-
plications of the tin isomer 117mSn in the context of its wider use in nuclear
medicine, particularly, in diagnostics. Until now, 117mSn has been used as
an effective agent for the palliation of pain from bone metastases. However,
the energy of gamma-rays emitted by 117mSn is optimal for scintigraphy
and, moreover, this tin isomer can also be connected to many different lig-
ands. Tin-117m can be effectively produced in many nuclear reactions with-
out the use of research reactors, which is a very big advantage particularly




Nuclear medicine is one of the specialties of medicine consisting in giv-
ing patients radiopharmaceuticals i.e. substances with radioactive isotopes
emitting ionizing radiation (photons, electrons and positrons) for the diag-
nosis and treatment of disease. In the diagnostics, two techniques of imaging
are applied. The first one is scintigraphy known also as a gamma scan based
on radioisotopes emitting gamma rays with an energy of a hundred keV up
to several hundred keV. The radioisotopes commonly used in scintigraphic
imaging are 99mTc, 123J and 81mKr [1–3]. Positron emission tomography
(PET) is the second main diagnostics technique. It uses the β+ emitters such
as 18F, 68Ga and many others [1, 4–9]. A good example of a radionuclide
used in radiopharmaceutical therapy is 131J [1, 10]. This iodine radioisotope
is applied for destruction of thyroid tissue in treatment of hyperthyroidism
and cancers. Recently, nuclear medicine has been strongly supporting the
advanced investigations in immunology. This branch of nuclear medicine is
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called radioimmunoassay [11]. An example of such studies can be in vitro
diagnostics determining amount of various substances such as drugs, hor-
mones and antibodies in blood [12–14]. The in vitro diagnostics is based on
radioisotopes of 125J, 14C and 3H [15].
1.2. Production of medical radioisotopes
Due to the rapid development of nuclear medicine, the demand for ra-
dioactive isotopes used in the diagnostics and the therapy is growing [16].
Currently, most medical radionuclides are produced by irradiation of ura-
nium disks (fission reactions) or targets enriched in the parent isotope (sim-
ple capture reactions (n.γ) called also radiative neutron capture) in research
reactors [16, 17]. The main suppliers of reactor-produced radioisotopes are
Belgium, Canada, The Netherlands, France, Poland and South Africa [16].
The radioisotopes with excessive neutrons (β− emitters) are mainly pro-
duced in research reactors, whereas those with excessive protons are pro-
duced in cyclotrons [18] in various reactions — (p, n), (p, p′n), (d, n) and
(γ, n). Nuclei with an excess of protons disintegrate by β+ decay. Therefore,
most of cyclotron radionuclides are suitable for application in the positron
emission tomography.
1.3. Technetium-99m
As already mentioned, technetium-99m is the basic radioisotope used in
nuclear medicine. This radionuclide has a relatively short half-life T1/2 =
6 hours which makes it impossible to use in medical centers far away from re-
search reactors. Therefore, the 99Mo/99mTc generators supplied from fission
production are applied (99Mo, T1/2 = 65.94 hours [19]). 85% of all nu-
clear medicine examinations use the 99Mo/99mTc generators for diagnostics
of liver, lungs, bones [20]. The shortage of 99mTc caused by the unexpected
prolonged shutdown of the Chalk River (Canada) and Petten (The Nether-
lands) reactors, and the permanent cessation of 99Mo production at The
Chalk River in 2016 contributed to the exploration of alternative methods
of producing 99mTc [21–23]. The non-reactor technetium-99m can be pro-
duced in a cyclotron by bombarding a 100Mo target with a 18 MeV proton
beam (in the (p, 2n) reaction) to produce 99mTc directly [21], or in a linear
accelerator to generate 99Mo in the photonuclear reaction 100Mo(γ, n)99Mo
induced by high-energy X-rays [21, 22]. IAEA recommends using medical
cyclotrons for the production of 99mTc [24]. A search for new radioisotopes
which could be an alternative to technetium-99m has also attracted signifi-
cant interest. The good candidate is the tin isomer — 117mSn. The purpose
of this paper is to review applications of 117mSn and ways of its production
in the context of replacing technetium-99m with tin-117m.
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2. Characteristic of tin-117m
117mSn is a nuclear isomer at the second exited state of tin. This state is
characterized by spin of 11/2, negative parity, excitation energy of 314.6 keV,
and a half-life T1/2 = 13.6 d [19, 24]. It disintegrates by a cascade gamma-
decay and internal conversion. The de-exciting transition energies of all
decay products of 117mSn are presented in Table I.
TABLE I
Characteristic of the 117mSn decay [17].
Emission intensity







3. Production of tin-117m
This tin isomer can be produced in a research reactor by two reac-
tions: the radiative neutron capture (n, γ) of enriched tin-116 (abundance
of 14.54%) and the neutron inelastic reaction (n, n′) on enriched tin-117
(7.68%). This second reaction is the most effective in higher flux reactors
since specific activity values of about two times higher than the radiative
TABLE II
The list of nuclear reactions leading to the formation of 117mSn.
Reaction Cross section Ref.
115In(α, pn) 16 mb at 31.5–35.4 MeV [26]
117S(p, p′γ) 0.37 mb at 23.6 MeV [27]
114Cd(α, n) 480 mb at 20 MeV [28]
116Cd(α, 3n) 1.2 b at 36 MeV [29]
121Sb(p, α) several hundred mb at 30–42 MeV [27]
118Sn(γ, n) 290 mb at 15 MeV [29]
116Sn(n, γ) 6 mb at thermal energies [30]
118Sn(n, n′) over 317.2 keV [30]
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capture reaction can be achieved [25]. Production using uranium disks is
ineffective because of very small amounts of tin-117m in the fission products.
However, 117mSn can be produced in cyclotrons and linear accelerators. The
characteristics of nuclear reactions leading to the formation of tin-117m are
shown in Table II.
4. Discussion of applications of tin-117m
Until now, 117mSn has been used as an effective agent for the palliation
of pain from bone metastases [31–33]. Such a radionuclide therapy leads to
the significant improvement of the quality of patients life. This application
results from the desired half-life of tin-117m, the energy of the emitted elec-
trons and the emission intensities of the internal conversions. Until now,
tin-117m has not been widely used in radiopharmaceuticals. At present, the
only radiopharmaceutical is tin(IV)-117m-DTPA (pentitic acid) [32] used
for the bone pain palliation. The main impediment for wider use of this
radioisotope is the low specific activity of tin-117m produced in research
reactors. Tin-117m can also be connected to other ligands as PyP (py-
rophosphate), EHDP (ethylidenehydroxy disodiumphosphonate) and MDP
(methylene diphosphonate) [32]. 117mSn is also a diagnostically promising
radioisotope, because it emits gamma rays of 158.6 keV, which is close to
the energy of 99mTc. This allows to use existing standard gamma camera
imaging, for example, to use the same collimator system as for technetium-
99m. Thus, the energy of gamma rays emitted by 117mSn is optimal for
scintigraphy. Higher energies cause loss of resolution of the scintigraphic
images, whereas lower energies cause the increase of a dose delivered to pa-
tients during examination. The relatively long half-life makes it possible to
use tin-117m without a generator. In consequence, the problem of the con-
tamination of radiopharmaceuticals with a parent radioisotope disappears.
In diagnostics, the contaminated radiopharmaceuticals are a source of an
additional dose to patients [34, 35].
5. Summary
Tin-117m is one of few medical radioisotopes that can be used in radio-
pharmaceutical therapy as well as in diagnostics. This tin isomer does not
require to apply a radionuclide generator because of its relatively long half-
life. Tin-117m can be effectively produced in many nuclear reactions without
the use of research reactors, which is a very big advantage particularly in
the light of the perceptible crisis in the production of technetium-99m.
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